Search Results | Blood | American Society of Hematology

1-20 of 516

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Introduction to a review series on pathophysiology and treatment of acute GVHD

Robert Zeiser

Blood (2020) 136 (4): 375–376.

DOI: https://doi.org/10.1182/blood.2019004271

Published: 2020

Journal Articles

Peri-Procedural Management and Outcomes of Patients with Hemophilia on Emicizumab Prophylaxis

Isabella McCary, BS, Christine Guelcher, PPCNP-BC, Jan Kuhn, BA, BSN, MSN, Regina Butler, RN-BC, Michael F. Guerrera, MD, Gita Massey, Leslie J. Raffini, MD

Blood (2019) 134 (Supplement_1): 2396.

DOI: https://doi.org/10.1182/blood-2019-126944

Published: 2019

Journal Articles

Prospective Controlled Monitoring of Hemlibra Prophylaxis Initiation in a Large Cohort of Hemophilia a Patients- Real World Data

Assaf Arie Barg, Tami Livnat, PhD, Tami Brutman-Barazani, Nurit Rosenberg, Ivan Budnik, MD PhD, Gili Kenet

Blood (2019) 134 (Supplement_1): 2397.

DOI: https://doi.org/10.1182/blood-2019-122010

Published: 2019

Journal Articles

A Phase I/II Dose-Escalation Study of Thiotepa-Based Immunochemotherapy in Relapsed/Refractory Primary Central Nervous System Lymphoma; The Tier Trial

Blood (2019) 134 (Supplement_1): 2879.

DOI: https://doi.org/10.1182/blood-2019-122830

Published: 2019

Journal Articles

Severe Cytokine Release Syndrome Is Associated with Impaired Hematopoietic Recovery after CD19-Targeted CAR-T Cell Therapy

Krishna R. Juluri, MD PhD, Alexandre V. Hirayama, MD, Erin Mullane, DNP, Nancy Cleary, BSc, Qian Vicky Wu, PhD, David G. Maloney, MD PhD, Cameron J. Turtle, MBBS, PhD, Merav Bar, MD, Jordan Gauthier, MD MSc

Blood (2019) 134 (Supplement_1): 3229.

DOI: https://doi.org/10.1182/blood-2019-126922

Published: 2019

Journal Articles

One Year Data from a Phase 2b Trial of AMT-061 (AAV5-Padua hFIX variant), an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-Severe Hemophilia B

Steven Pipe, MD, Adam Giermasz, MD PhD, Giancarlo Castaman, MD, Nigel S. Key, MBChB, FRCP, Susan U Lattimore, Frank Leebeek, MD PhD, Wolfgang Miesbach, MD PhD, Michael Recht, MD PhD, Esteban Gomez, MD, Alison Long, Robert Gut, Annette von Drygalski, MD PharmD

Blood (2019) 134 (Supplement_1): 3348.

DOI: https://doi.org/10.1182/blood-2019-128765

Published: 2019

Journal Articles

CD20 Targeted CAR-T for High-Risk B-Cell Non-Hodgkin Lymphomas

Mazyar Shadman, MD, Ajay K. Gopal, MD, Stephen D. Smith, MD, Ryan C. Lynch, MD, Chaitra S. Ujjani, MD, Cameron J. Turtle, MBBS, PhD, Adam Greenbaum, MD PhD, Mary Redman, Cecilia Yeung, MD, Martina Sersch, MD PhD, Edus H. Warren, MD PhD, David G. Maloney, MD PhD, Brian G. Till, MD

Blood (2019) 134 (Supplement_1): 3235.

DOI: https://doi.org/10.1182/blood-2019-125102

Published: 2019

Journal Articles

Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Results from Arm C of the Sequoia (BGB-3111-304) Trial

Blood (2019) 134 (Supplement_1): 499.

DOI: https://doi.org/10.1182/blood-2019-125394

Published: 2019

Journal Articles

Predictors of Efficacy for Blinatumomab in BCP-ALL Patients: Non-Responders Show Impaired CD19-BiTE®-Mediated Cytotoxicity in Vitro

Veit Bücklein, MD, Michaela Scheurer, Bettina Brauchle, MSc, Roman Kischel, MD, Michael von Bergwelt, Karsten Spiekermann, MD, Marion Subklewe, MD

Blood (2019) 134 (Supplement_1): 2632.

DOI: https://doi.org/10.1182/blood-2019-129057

Published: 2019

Journal Articles

PI3Kδ Inhibition Enhances Sensitivity of Primary High-Risk Childhood B-Cell Acute Lymphoblastic Leukemia Cells to Glucocorticoid Chemotherapy

Jessica A.O. Zimmerman, MD, Mimi Fang, Arunkumar Modi, MBBS, MPH, Adam Dupuy, PhD, Sarah K. Tasian, MD, Miles A. Pufall, PhD

Blood (2019) 134 (Supplement_1): 2572.

DOI: https://doi.org/10.1182/blood-2019-129205

Published: 2019

Journal Articles

Evaluation of a Bifunctional Sirpα-CD123 Fusion Antibody for the Elimination of Acute Myeloid Leukemia Stem Cells

Siret Tahk, Saskia Schmitt, Christian Peter Augsberger, Binje Vick, PhD, Laia Pascual Ponce, PhD, Irmela Jeremias, MD PhD, Georg Wittmann, MD, Nadja Fenn, PhD, Marion Subklewe, MD, Karl-Peter Hopfner, PhD

Blood (2019) 134 (Supplement_1): 2544.

DOI: https://doi.org/10.1182/blood-2019-128145

Published: 2019

Journal Articles

First-in-human Gene Therapy Study of AAVhu37 Capsid Vector Technology in Severe Hemophilia A

Steven Pipe, MD, Michael Becka, Elke Detering, Konstantina Vanevski, Toshko Lissitchkov

Blood (2019) 134 (Supplement_1): 4630.

DOI: https://doi.org/10.1182/blood-2019-125764

Published: 2019

Journal Articles

Clinical Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Transfusion-Dependent β-Thalassemia Treated at the Bambino Gesù Children's Hospital, Rome, Italy

Pietro Merli, MD, Annalisa Ruggeri, MD, Mattia Algeri, MD, Giuseppina Li Pira, PhD, Giulia Ceglie, MD, Katiana Gruppioni, MPH, Sanjeev Kommera, MS, Jenfue Maa, PhD, Franco Locatelli, MD PhD

Blood (2019) 134 (Supplement_1): 969.

DOI: https://doi.org/10.1182/blood-2019-123440

Published: 2019

Journal Articles

Treatment Outcomes with Purine Nucleoside Analog Alone or with Rituximab for Hairy Cell Leukemia Patients at First Relapse: A Multi-Center Outcomes Analysis

Rachel Hu, MD, Wei Wei, MS, Kristen Gonter-Aubin, DO, Javier Pinilla Ibarz, MD PhD, Charlene C. Kabel, PharmD, Anthony R. Mato, MDMSCE, Yazan F. Madanat, MD, Sirin Khajavian, MD, Mazyar Shadman, MD, Ashley Hanlon, MD, Danielle M. Brander, MD, Jae H. Park, MD, Martin S. Tallman, MD, Brian T. Hill, MD

Blood (2019) 134 (Supplement_1): 4004.

DOI: https://doi.org/10.1182/blood-2019-126381

Published: 2019

Journal Articles

A Novel CD19-Anti-CD20 Bridging Protein Prevents and Reverses CD19-Negative Relapse from CAR19 T Cell Treatment In Vivo

Paul Rennert, PhD, Lihe Su, PhD, Fay Dufort, PhD, Alyssa Birt, MS, Tom Sanford, Lan Wu, PhD, Christine Ambrose, PhD, Roy Lobb, PhD

Blood (2019) 134 (Supplement_1): 252.

DOI: https://doi.org/10.1182/blood-2019-130654

Published: 2019

Journal Articles

Factors Associated with Response, CAR-T Cell In Vivo Expansion, and Progression-Free Survival after Repeat Infusions of CD19 CAR-T Cells

Evandro D. Bezerra, MD, Jordan Gauthier, MD MSc, Alexandre V. Hirayama, MD, Barbara S. Pender, MSc, Reed M. Hawkins, BS, Aesha Vakil, MSc, Rachel N. Steinmetz, BS, Aude G. Chapuis, MD, Brian G. Till, MD, Hans-Peter Kiem, MD PhD, Mazyar Shadman, MD MPH, Ryan D. Cassaday, MD, Stanley R. Riddell, MD, David G. Maloney, MD PhD, Cameron J. Turtle, MBBS, PhD

Blood (2019) 134 (Supplement_1): 201.

DOI: https://doi.org/10.1182/blood-2019-123807

Published: 2019

Journal Articles

Real-World Use of Emicizumab in Patients with Hemophilia with and without Inhibitors

Isabella McCary, BS, Christine Guelcher, PPCNP-BC, Jan Kuhn, BA, BSN, MSN, Regina Butler, RN-BC, Gita Massey, Michael F. Guerrera, MD, Lance Ballester, MS, Leslie J. Raffini, MD

Blood (2019) 134 (Supplement_1): 1137.

DOI: https://doi.org/10.1182/blood-2019-122569

Published: 2019

Journal Articles

Fitusiran, an RNAi Therapeutic Targeting Antithrombin to Restore Hemostatic Balance in Patients with Hemophilia a or B with or without Inhibitors: Management of Acute Bleeding Events

Steven Pipe, MD, Margaret V. Ragni, MD MPH, Claude Négrier, MD PhD, Qifeng Yu, PhD, Naghmana Bajwa, MD, John Caminis, MD, Baisong Mei, MD PhD, Shauna R. Andersson, MD PhD

Blood (2019) 134 (Supplement_1): 1138.

DOI: https://doi.org/10.1182/blood-2019-124108

Published: 2019

Journal Articles

The Immune Response to Murine Factor VIII in Single Exon Deletion and Total Gene Deletion Murine Models of Hemophilia a

Seema R Patel, PhD, Wallace H. Baldwin, Courtney Cox, MSc, John Healey, BS, Ernest T. Parker, Glaivy Batsuli, MD, Shannon L. Meeks, MD

Blood (2019) 134 (Supplement_1): 1109.

DOI: https://doi.org/10.1182/blood-2019-130890

Published: 2019

Journal Articles

The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Novel Comorbidity Score Derived from a Large Multicenter Retrospective Cohort Study of Patients Treated with Ibrutinib and/or Chemo-Immunotherapy (CIT)

Max J. Gordon, MD, Andy Kaempf, Andrea Sitlinger, MD, Tareq Salous, Hamood Alqahtani, MBBS, Michael C. Churnetski, Paul Wisniewski, Xavier Issac Rivera, BS, Krish Patel, MD, Daniel O. Persky, MD, Jonathon B. Cohen, MDMS, Michael Y. Choi, MD, Brian T. Hill, MD, Mazyar Shadman, MD, Deborah M. Stephens, DO, Danielle M. Brander, MD, Byung Park, PhD, Alexey Danilov, MD PhD

Blood (2019) 134 (Supplement_1): 4286.

DOI: https://doi.org/10.1182/blood-2019-124631

Published: 2019

2 3 4 5

NARROW

Introduction to a review series on pathophysiology and treatment of acute GVHD

Peri-Procedural Management and Outcomes of Patients with Hemophilia on Emicizumab Prophylaxis

Prospective Controlled Monitoring of Hemlibra Prophylaxis Initiation in a Large Cohort of Hemophilia a Patients- Real World Data

A Phase I/II Dose-Escalation Study of Thiotepa-Based Immunochemotherapy in Relapsed/Refractory Primary Central Nervous System Lymphoma; The Tier Trial

Severe Cytokine Release Syndrome Is Associated with Impaired Hematopoietic Recovery after CD19-Targeted CAR-T Cell Therapy

One Year Data from a Phase 2b Trial of AMT-061 (AAV5-Padua hFIX variant), an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-Severe Hemophilia B

CD20 Targeted CAR-T for High-Risk B-Cell Non-Hodgkin Lymphomas

Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Results from Arm C of the Sequoia (BGB-3111-304) Trial

Predictors of Efficacy for Blinatumomab in BCP-ALL Patients: Non-Responders Show Impaired CD19-BiTE®-Mediated Cytotoxicity in Vitro

PI3Kδ Inhibition Enhances Sensitivity of Primary High-Risk Childhood B-Cell Acute Lymphoblastic Leukemia Cells to Glucocorticoid Chemotherapy

Evaluation of a Bifunctional Sirpα-CD123 Fusion Antibody for the Elimination of Acute Myeloid Leukemia Stem Cells

First-in-human Gene Therapy Study of AAVhu37 Capsid Vector Technology in Severe Hemophilia A

Clinical Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Transfusion-Dependent β-Thalassemia Treated at the Bambino Gesù Children's Hospital, Rome, Italy

Treatment Outcomes with Purine Nucleoside Analog Alone or with Rituximab for Hairy Cell Leukemia Patients at First Relapse: A Multi-Center Outcomes Analysis

A Novel CD19-Anti-CD20 Bridging Protein Prevents and Reverses CD19-Negative Relapse from CAR19 T Cell Treatment In Vivo

Factors Associated with Response, CAR-T Cell In Vivo Expansion, and Progression-Free Survival after Repeat Infusions of CD19 CAR-T Cells

Real-World Use of Emicizumab in Patients with Hemophilia with and without Inhibitors

Fitusiran, an RNAi Therapeutic Targeting Antithrombin to Restore Hemostatic Balance in Patients with Hemophilia a or B with or without Inhibitors: Management of Acute Bleeding Events

The Immune Response to Murine Factor VIII in Single Exon Deletion and Total Gene Deletion Murine Models of Hemophilia a

The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Novel Comorbidity Score Derived from a Large Multicenter Retrospective Cohort Study of Patients Treated with Ibrutinib and/or Chemo-Immunotherapy (CIT)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only